{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:58:35Z","timestamp":1763017115732},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T00:00:00Z","timestamp":1306108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T00:00:00Z","timestamp":1306108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/bmt.2011.106","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T10:46:05Z","timestamp":1306147565000},"page":"516-521","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma"],"prefix":"10.1038","volume":"47","author":[{"given":"A I","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L J","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D B","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W-K","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G G","family":"Laport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,23]]},"reference":[{"key":"BFbmt2011106_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2011106_CR2","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt2011106_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg\/m(2) melphalan and 8 Gy total body irradiation plus 140\u2009mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BFbmt2011106_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BFbmt2011106_CR5","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434\u20132441.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011106_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.","journal-title":"Blood"},{"key":"BFbmt2011106_CR7","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/cncr.20294","volume":"100","author":"A Anagnostopoulos","year":"2004","unstructured":"Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004; 100: 2607\u20132612.","journal-title":"Cancer"},{"key":"BFbmt2011106_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","volume":"130","author":"R Fenk","year":"2005","unstructured":"Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005; 130: 588\u2013594.","journal-title":"Br J Haematol"},{"key":"BFbmt2011106_CR9","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","volume":"13","author":"E Carreras","year":"2007","unstructured":"Carreras E, Rosinol L, Terol MJ, Alegre A, de Arriba F, Garcia-Larana J et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007; 13: 1448\u20131454.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011106_CR10","first-page":"160","volume":"6","author":"TL Taylor","year":"2000","unstructured":"Taylor TL, Hu WW, Johnston LJ, Shizuru JA, Negrin RS, Chao NJ et al. Total body irradiation does not affect outcome in patients autografted for multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 160.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011106_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt2011106_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011106_CR13","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447\u20133454.","journal-title":"Blood"},{"key":"BFbmt2011106_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/jnci\/85.8.640","volume":"85","author":"RB Jones","year":"1993","unstructured":"Jones RB, Matthes S, Shpall EJ, Fisher JH, Stemmer SM, Dufton C et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640\u2013647.","journal-title":"J Natl Cancer Inst"},{"key":"BFbmt2011106_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.leu.2404003","volume":"20","author":"RL Comenzo","year":"2006","unstructured":"Comenzo RL, Hassoun H, Kewalramani T, Klimek V, Dhodapkar M, Reich L et al. Results of a phase I\/II trial adding carmustine (300\u2009mg\/m2) to melphalan (200\u2009mg\/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia 2006; 20: 345\u2013349.","journal-title":"Leukemia"},{"key":"BFbmt2011106_CR16","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.","journal-title":"Blood"},{"key":"BFbmt2011106_CR17","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131\u20133136.","journal-title":"Blood"},{"key":"BFbmt2011106_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176\u2013185.","journal-title":"Br J Haematol"},{"key":"BFbmt2011106_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1200\/JCO.2007.11.6863","volume":"26","author":"W Bensinger","year":"2008","unstructured":"Bensinger W . Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008; 26: 480\u2013492.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011106_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","volume":"115","author":"M Roussel","year":"2010","unstructured":"Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32\u201337.","journal-title":"Blood"},{"key":"BFbmt2011106_CR21","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289\u20133294.","journal-title":"Blood"},{"key":"BFbmt2011106_CR22","doi-asserted-by":"crossref","unstructured":"McCarthy PL, Owzar K, Stadtmauer EA, Giralt S, Hurd DD, Hassoun H et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma: CALGB 100104. J Clin Oncol 2010; 28 (15\u2009s): Abstract no. 8017.","DOI":"10.1200\/jco.2010.28.15_suppl.8017"},{"issue":"15_suppl","key":"BFbmt2011106_CR23","doi-asserted-by":"publisher","first-page":"8018","DOI":"10.1200\/jco.2010.28.15_suppl.8018","volume":"28","author":"M. Attal","year":"2010","unstructured":"Attal M, Cristini C, Marit G, Caillot D, Facon T, Hullin C et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol 2010; 28 (15\u2009s): Abstract no. 8018.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:18:12Z","timestamp":1648041492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,23]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFbmt2011106"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.106","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,23]]},"assertion":[{"value":"12 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}